Diabetes & Metabolism Journal10.4093/dmj.2012.36.4.2622012364262GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver DiseaseJinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Won-Young Lee,,
Journal of Hepatology10.1016/s0168-8278(20)30765-0202073S124HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trialManal Abdelmalek, Jaeduk Choi, Youngmin Kim, Kyounghee Seo, Marcus Hompesch, Seungjae Baek,
Journal of Gastroenterology and Hepatology10.1046/j.1440-1746.17.s1.10.x200217S186-S190Non-alcoholic fatty liver diseasePAUL ANGULO, KEITH D LINDOR,,
Archives of Hepatitis Research10.17352/ahr.000014201731029-036Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A ReviewS Singh, KK Kharbanda
Journal of Gastroenterology and Hepatology10.1046/j.1440-1746.17.s3.32.x200217S385-S388Treatment of non-alcoholic fatty liver diseaseARUN J SANYAL,,
Journal of Diabetes10.1111/j.1753-0407.2012.00204.x201243266-280Non-alcoholic fatty liver diseaseAna C. TUYAMA, Charissa Y. CHANG,
Alimentary Pharmacology & Therapeutics10.1046/j.1365-2036.2003.01493.x2003178977-986Non-alcoholic fatty liver diseaseL. M. Alba, K. Lindor,,
Hepatology Research10.1111/j.1872-034x.2011.00867.x20114110911-920Clinicopathological features of non-alcoholic fatty liver diseaseKazushi Sugimoto, Yoshiyuki Takei
Journal of Gastroenterology and Hepatology10.1111/jgh.1224220132879-80Treatment of non-alcoholic fatty liver diseaseYoshiyuki Takei,,
Gastroenterology10.1016/s0016-5085(18)33839-320181546S-1159Su1498 - A Highly Selective and Potent Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity (NAS) in two Murine Models of Non-Alcoholic Steatohepatitis (NASH)Li-Juan Jiang, Mary Chau, Yang Li, Yat Sun Or,